AN UNBIASED VIEW OF AGO TUMOR

Molecular typing is predicated on molecular genetic testing and is not but routinely obtainable. Molecular subtypes and immunohistochemical surrogate markers with the tumors (HR, HER2, triple adverse) correlate in about 70%. The differentiation of luminal A and B subtypes by HR position and proliferation markers like Ki-sixty seven may very well be